Medicare Part D already covers GLP-1 drugs for use in diabetes patients, and spending on the drug class has catapulted in recent years from $57 million in 2018 to $5.7 billion in 2022, according to an analysis from health policy research firm KFF
Several Prader-Willi syndrome drugs are currently in mid and late-stage development, with potential approvals on the horizon
Common neural targets for obesity treatment Emerging evidence suggests that both GLP-1RAs and physical exercise converge on common neural pathways, influencing brain regions involved in appetite regulation, energy balance, and cognitive function
This is seen initially with taking the medication, usually occurring in the first weeks, wanes with time
There is plenty of frustration in getting it wrong
Treatment usually begins with a lower dose to help your body adjust comfortably